DeepMed Research

Taisho Pharmaceutical Co., Ltd.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Subsidiary

Employees: 5.6K

Market Cap: -

Website: http://www.taisho.co.jp

Clinical Trials

Late Phase II Study of TS-142 in Patients with Insomnia

Phase 2

Completed

Conditions: Patients with Insomnia

Interventions: Drug: TS-142

First Posted Date: 2020-07-13

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 179

Registration Number: NCT04469023

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: TS-142, 10 mg
Drug: TS-142, 20 mg
Drug: TS-142, 30 mg

First Posted Date: 2019-11-20

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04169906

Locations: 🇯🇵
The medical facility selected by Taisho Pharmaceutical Co., Ltd, Fukuoka, Japan

A Phase I Study of TS-142 in Healthy Participants (Single Doses)

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo (fasting)
Drug: Placebo (feeding)
Drug: 1 mg of TS-142
Drug: 10 mg of TS-142 (feeding)
Drug: 3 mg of TS-142
Drug: 10 mg of TS-142 (fasting)
Drug: 30 mg of TS-142

First Posted Date: 2019-11-20

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT04169893

Locations: 🇯🇵
The medical facility selected by Taisho Pharmaceutical Co., Ltd, Fukuoka, Japan

Development and Validation of a Driving Simulator for Evaluating the Residual Effects of Drugs on Driving Performance - Sensitivity Analysis Using Zopiclone As a Positive Control

Not Applicable

Completed

Conditions: Healthy Participants

Interventions: Other: Road-tracking test
Other: Car-following test
Other: Harsh-braking test

First Posted Date: 2019-09-30

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT04108351

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Fukuoka, Japan
🇯🇵
The medical facility selected by Taisho Pharmaceutical Co., Ltd, Fukuoka, Japan

Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects

Phase 2

Completed

Conditions: Healthy Volunteer

First Posted Date: 2019-09-12

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 23

Registration Number: NCT04087707

Locations: 🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan

An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: TS-152

First Posted Date: 2019-09-04

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 401

Registration Number: NCT04077567

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TS-143
Drug: Placebo

First Posted Date: 2018-07-23

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT03595202

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TS-143
Drug: Placebo

First Posted Date: 2018-07-19

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT03591133

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients with Chronic Kidney Disease

Phase 1

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: TS-143

First Posted Date: 2018-07-10

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 29

Registration Number: NCT03581071

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo and other Japanese city, Japan

Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #3

Not Applicable

Completed

Conditions: Healthy Participants

Interventions: Other: Road-tracking test
Other: Car-following test
Other: Harsh-braking test

First Posted Date: 2018-06-28

Last Posted Date: 2025-02-28

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 25

Registration Number: NCT03572985

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Fukuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy